Tucatinib (Tukysa) added to maintenance therapy for HER2-positive metastatic breast cancer
FDA approval — October 7, 2026
What was approved
On October 7, 2026, the FDA approved tucatinib (brand name Tukysa, from Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer, following induction treatment.
In plain English: “maintenance” is the treatment that continues after the first round — here, 4 to 8 cycles of trastuzumab, pertuzumab, and a taxane chemotherapy — has kept the cancer from progressing. The idea is to keep it that way for longer. HER2-positive means the cancer cells carry extra copies of a growth signal called HER2; all three of these drugs target that signal. Tucatinib is a pill (300 mg, taken twice a day); the other two are given by infusion or injection.
The evidence
The approval rests on HER2CLIMB-05 (NCT05132582), a Phase 3 trial that randomly assigned 654 adults whose cancer had not progressed after induction treatment to tucatinib or a placebo, on top of trastuzumab and pertuzumab. It was double-blind — neither patients nor their doctors knew who got the real drug. Results were published in the Journal of Clinical Oncology.
The headline result, as the FDA states it: median progression-free survival — the time until the cancer grew or the patient died — was 24.9 months with tucatinib versus 16.3 months without it (hazard ratio 0.64; p < 0.0001). In absolute terms, that is an 8.6-month difference in medians. Overall survival data were not yet mature when this was analyzed, so the trial has not yet shown whether patients live longer overall — only that the cancer stayed controlled longer.
On safety, the label carries a boxed warning — the FDA's strongest — for liver toxicity (hepatotoxicity), plus warnings for diarrhea and embryo-fetal toxicity.
The grade: Promising (evidence score 12 of 14)
Run through the Breakthrough Evidence Checker's 7 checks:
| Check | Result | Why |
| 1. Tested in people | Yes | Tested in 654 adults with the condition, in a Phase 3 trial. |
| 2. Decent size | Yes | Hundreds of participants — well past the “hundreds or more” bar. |
| 3. Peer-reviewed | Yes | Published in the Journal of Clinical Oncology, not just announced in a press release. |
| 4. Replicated | No | One pivotal trial. No independent team has repeated the result yet. |
| 5. Independent funding | No | The trial was run by the drug's maker, Seagen/Pfizer, which profits from a positive result. |
| 6. Absolute numbers | Yes | The FDA reports the actual medians — 24.9 vs. 16.3 months — not only a relative “36% lower risk.” |
| 7. Randomized controlled trial | Yes | Randomized, double-blind, and placebo-controlled — the strongest standard design. |
“Promising” in the checker's words means: real signals — but gaps worth knowing about. The gaps here are the missing replication, the maker's funding, and the unanswered survival question. It does not mean the case is closed.
Who it affects
Adults whose breast cancer is HER2-positive, is locally advanced and cannot be removed by surgery or has spread to other parts of the body, and did not progress during the initial induction treatment described above. The trial included patients with and without brain metastases. Whether this treatment fits any individual situation is a question for that person's own care team — this entry only explains the approval.
Cost
The FDA approves drugs; it does not set or announce their prices, and its notice lists none. What this regimen costs a given patient will depend on pricing set by the maker and on that patient's coverage — figures not established by the approval announcement, so none are quoted here.
Source
U.S. Food and Drug Administration, “FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer,” October 7, 2026: fda.gov approval notice
Honed Proof provides health information for general purposes only — not medical advice, diagnosis, or treatment. Always talk to a qualified health professional about your own care.
Atezolizumab (Tecentriq) with chemotherapy after surgery for Stage III dMMR colon cancer
FDA approval — October 8, 2026
What was approved
On October 8, 2026, the FDA approved atezolizumab (brand name Tecentriq, from Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin — standard chemotherapy drugs — for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved the under-the-skin form, atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza), with the same chemotherapy, for patients 12 years and older who weigh at least 40 kg.
In plain English: “adjuvant” means treatment given after the main treatment — here, after surgery removed the tumor completely — to lower the chance the cancer comes back. Stage III means the cancer had reached nearby lymph nodes. dMMR means the tumor's DNA proofreading system is broken, a feature found in a minority of colon cancers; it is also the feature that makes this kind of immune-system drug (atezolizumab helps the immune system attack cancer cells) a plausible match. Eligibility is set by testing the tumor for mismatch repair status.
The evidence
The approval rests on the ATOMIC trial (NCT02912559), a Phase 3 study run at many centers that randomly assigned 712 patients (711 adults and one pediatric patient) whose Stage III dMMR colon cancer had been completely removed by surgery. Half received atezolizumab with mFOLFOX6 chemotherapy for 12 cycles, followed by atezolizumab alone for six months; half received mFOLFOX6 alone. Results were published in the New England Journal of Medicine in March 2026.
The headline result, as the FDA states it: the hazard ratio for disease-free survival was 0.50 (p = 0.0001) — the rate of cancer recurrence or death was cut in half. In the absolute numbers the headlines usually skip: at three years, 86.3% of the atezolizumab group versus 76.2% of the chemotherapy-only group were free of recurrence or death — roughly 10 more people in every 100. Median disease-free survival was not reached in either group. Overall survival did not differ significantly between the groups in the data reported so far (five-year rates of 89.7% versus 87.9%).
On safety, the label warns about immune-mediated adverse reactions — the immune system attacking healthy tissue — infusion-related reactions, complications around stem-cell transplantation, and embryo-fetal toxicity.
The grade: Promising (evidence score 11 of 14)
Run through the Breakthrough Evidence Checker's 7 checks:
| Check | Result | Why |
| 1. Tested in people | Yes | Tested in 712 patients with the condition, in a Phase 3 trial. |
| 2. Decent size | Yes | Hundreds of participants. |
| 3. Peer-reviewed | Yes | Published in the New England Journal of Medicine. |
| 4. Replicated | No | One pivotal trial so far; no independent replication yet. |
| 5. Independent funding | Unsure | ATOMIC was led by the Alliance cooperative research group and Mayo Clinic investigators rather than run directly by the maker — but Genentech, which sells the drug, was involved in supporting it. Not a clean yes either way, and “unsure” is an honest answer. |
| 6. Absolute numbers | Yes | Three-year disease-free survival of 86.3% vs. 76.2% is reported alongside the relative “risk cut in half.” |
| 7. Randomized controlled trial | Yes | Randomized against an active control (chemotherapy alone). It was open-label — everyone knew who got what — which is a notch below blinded, but the design is still a randomized controlled trial. |
“Promising” in the checker's words means: real signals — but gaps worth knowing about. Here the gaps are the single unreplicated trial and a survival picture that so far shows a recurrence benefit without a significant overall-survival difference. It does not mean the case is closed.
Who it affects
People — adults, and children from age two for the intravenous form — whose colon cancer was Stage III, whose tumor tests as mismatch repair deficient (dMMR), and whose tumor was completely removed by surgery. dMMR tumors are a minority of colon cancers, so this approval covers a defined subset, not colon cancer generally. Whether it fits any individual situation is a question for that person's own care team — this entry only explains the approval.
Cost
The FDA approves drugs; it does not set or announce their prices, and its notice lists none. What this regimen costs a given patient will depend on pricing set by the maker and on that patient's coverage — figures not established by the approval announcement, so none are quoted here.
Source
U.S. Food and Drug Administration, “FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer,” October 8, 2026: fda.gov approval notice
Honed Proof provides health information for general purposes only — not medical advice, diagnosis, or treatment. Always talk to a qualified health professional about your own care.